Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus
Desmopressin for nocturnal enuresis in nephrogenic diabetes insipidus
复制标题
去氨加压素治疗肾性尿崩症夜间遗尿
DOI：
10.1016/s0140-6736(02)07667-5
复制
发表时间：
2002
期刊：
影响因子：
--
通讯作者：
P. Deen
中科院分区：
文献类型：
--
作者：
D. Müller;Nannette Marr;T. Ankermann;P. Eggert;P. Deen
我们调查了两个不相关的家庭，其中两个孩子遗传了原发性夜间遗尿症，以及由水通道蛋白2基因（AQP2）新突变引起的肾性尿崩症。突变的 AQP2 蛋白没有活性，表明给予去氨加压素不能浓缩这些患者的尿液。然而，去氨加压素治疗完全解决了原发性夜间遗尿症。这一观察结果对去氨加压素仅通过药物操纵肾脏浓缩能力来解决原发性夜间遗尿症的观点提出了质疑。去氨加压素还可能作用于肾外靶标，例如中枢神经系统。
We have investigated two unrelated families, in which two children had inherited primary nocturnal enuresis, and nephrogenic diabetes insipidus caused by new mutations in the aquaporin-2 gene (AQP2). The mutant AQP2 proteins were inactive, suggesting that administration of desmopressin could not concentrate the urine in these patients. However, treatment with desmopressin resolved primary nocturnal enuresis completely. This observation questions the notion that desmopressin resolves primary nocturnal enuresis through pharmacological manipulation of renal concentrating ability only. Desmopressin might also act on extrarenal targets such as the central nervous system.